| This week's sponsor is CMIC Group. | |  | Considering Japanese Market Entry?
As Japan's largest CRO with end-to-end solution, CMIC Group is your most experienced partner in Japan & the US. Our experts will help you determine the best strategy at any stage of drug development.
Click here to learn more! |
Today's Rundown Featured Story | | | Friday, March 22, 2019 Albert Einstein is often attributed as saying: “The definition of insanity is doing the same thing over and over again, but expecting different results.” He likely didn’t actually say this, but regardless of its origins, this witticism comes sharply into focus when you read Eisai’s press release about starting new trials for BAN2401. |
|
|
Top Stories Friday, March 22, 2019 Johnson & Johnson has abandoned development of anti-RSV drug AL-8176, wiping another $900 million off the value of the assets it acquired from Alios Biopharma. The writedown comes months after J&J took a $630 million hit tied to the suspension of clinical development of AL-8176. Friday, March 22, 2019 Conatus Pharmaceuticals’ emricasan has failed another midphase clinical trial. The latest setback saw the Novartis-partnered liver disease drug fail to beat placebo in NASH patients, wiping another 50% off Conatus’ stock price. Friday, March 22, 2019 Patients taking GlaxoSmithKline’s anti-BCMA treatment for multiple myeloma had an overall response rate of 60% and median progression-free survival of one year, new phase 1 data show. The Big Pharma expects pivotal data for the candidate by the end of the year. Friday, March 22, 2019 Turning Point Therapeutics has filed to raise up to $100 million in its Nasdaq debut. The proceeds will push its lead asset, repotrectinib, into phase 2 studies and to advance a pair of earlier-stage programs in advanced solid tumors. Thursday, March 21, 2019 In this week's EuroBiotech Report, Alexion strikes deals with European biotechs, Nightstar discusses a Biogen deal and Genfit sets IPO terms. Friday, March 22, 2019 Biogen and Eisai's Alzheimer's candidate aducanumab didn't make it through phase 3 testing; analysts argue Keytruda could see blockbuster sales in China thanks to its stellar clinical profile; South Korean prosecutors raid Korea Exchange offices in Samsung BioLogics probe; and more. Friday, March 22, 2019 NGM Bio gains a Genentech and Lilly veteran as new R&D chief, as Forma nabs a longtime Genentech commercial executive as CEO. Meanwhile, Nimbus builds out its team with new heads of biology and preclinical development. Those moves plus more hirings, firings and retirings throughout the industry. | This week's sponsor is Accenture. | |  | [Webinar] Embracing Emerging Technology in Drug Development
Wednesday, March 27 | 10am ET / 7am PT
During this webinar, attendees will learn how organizations can rapidly adopt digital solutions while maintaining a focus on the patient, harmonize a rapidly transforming workforce with new technological capabilities, and align new technologies with an organization's R&D strategy and goals for profitable growth. Register Now! |
Resources Sponsored by: Outer Edge Technology Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: InterSystems Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories. Sponsored by: InterSystems Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs. Sponsored by: Patheon, part of Thermo Fisher Scientific The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: ON24 Which HCP Touchpoints and channels are yielding the best results in today’s digital world? Sponsored by: Blue Matter White paper outlining the key types of cell-based immunotherapies in oncology, as well as the development and commercial outlook for each. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
